Adherence to recommended immunization schedule during adolescence: findings of a cross-sectional study in the Southern part of Italy Authors: Francesca Licata, Concetta Arianna Scicchitano, Francesca Ficara, Gianfranco Di Gennaro, Aida Bianco Published: 2026 ABSTRACT BackgroundAdolescence is a pivotal life stage during which individuals develop health-related attitudes and behaviours that frequently persist into adulthood, making it a crucial period for shaping long-term engagement with preventive care. Despite Italy’s national recommendations for adolescent vaccines (HPV, MenACWY, and the dTap-IPV booster), coverage gaps persist. By analyzing the self-reported vaccination history of university students, this study aims to assess adolescent vaccine adherence, willingness to vaccinate and their predictors to better inform targeted public health interventions.MethodsA cross-sectional survey was conducted among university students (aged 18–29 years). An online, anonymous, self-administered questionnaire was developed to gather data on socio-demographic characteristics, past adherence to vaccinations offered during adolescence (i.e., HPV and MenACWY vaccines and the dTap-IPV booster), willingness to get vaccinated, factors influencing vaccination decision making, and sources of information on vaccinations.ResultsAmong the 527 enrolled participants, 29% reported having received the MenACWY vaccine during adolescence, with the lack of healthcare worker (HCW) recommendation cited as the leading barrier (59.4%). HPV vaccine uptake was the strongest predictor of being vaccinated against MenACWY vaccination. A majority of the students (68.3%) reported receiving the HPV vaccine during adolescence, primarily to prevent HPV-related cancers (55.8%). Female sex, younger age, and higher parental education were positively associated with the HPV vaccine uptake. Additionally, 89.4% received the dTap-IPV booster, and this uptake was positively associated with both HPV and MenACWY vaccination. Notably, one-third (31.1%) reported that an HCW had discouraged vaccination, and even though nearly all (99.4%) cited HCWs as their primary source of information on vaccination.ConclusionsA persistent gap in adolescent vaccination adherence remains, particularly for MenACWY and HPV, driven by unbalanced risk perceptions and frequent missed clinical opportunities by HCWs. Conversely, vaccine mandates ensured high dTap-IPV coverage. The strong correlation across vaccine types highlights the potential of “clustered” immunization behaviors. To bridge these coverage gaps, interventions must strengthen HCW counseling, utilize low-friction delivery models like school-based clinics, and deploy dual-targeted strategies that reframe vaccination as a shared social responsibility.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12889-026-27991-0. Background Vaccination stands as one of the cornerstones of modern public health, playing a vital role in the prevention of acute and chronic infectious diseases across the entire lifespan. Despite the well-documented benefits of vaccination across all age groups, immunization programs have historically centered on early childhood, with comparatively less attention directed toward other age groups, such as adolescents [1]. A variety of vaccines, including primary immunizations, booster doses, and catch-up programs, are recommended for this demographic. Currently, in Italy, the National Immunization Prevention Plan 2023–2025 offers several vaccinations for adolescents aged 11 to 18 years, namely, the quadrivalent vaccination targeting meningococcal serogroups A, C, Y, and W-135 (MenACWY), the 9-valent Human Papilloma Virus (HPV) vaccine, and a booster against diphtheria, tetanus, pertussis (dTap) and poliomyelitis (IPV), the latter of which is mandated by law [2]. The MenACWY vaccine was introduced free of charge in 2017 for adolescents aged 11 to 18 years [3]. It is now offered starting from the 12th month of life (replacing the serogroup C meningococcal vaccine [MenC]), with a booster recommended between 12 and 18 years of age [2]. The MenACWY vaccine is also recommended for previously unvaccinated individuals at increased risk of invasive meningococcal disease (IMD) due to medical conditions, and for travelers to countries where meningococcal disease is hyperendemic or epidemic [2 ]. HPV vaccination has been offered to teenage girls free of charge since 2007, progressively expanding to a gender-neutral program in 2015 and transitioning from bivalent or quadrivalent to the nonavalent formulation in 2017 [3]. The dTap-IPV booster represents one of the longest-standing immunization interventions in the Italian vaccination schedule. It is mandatory at 5 to 6 years of age, typically as a tetravalent vaccine, followed by a fifth dose between 12 and 18 years of age. To maintain immunity, adults are recommended to receive a dTap booster every ten years. Vaccination adherence, which is crucial for community immunity, often remains suboptimal, even when vaccinations are offered free of charge. In Italy, available data indicate that adherence to HPV and MenACWY vaccines, as well as the dTap-IPV booster during adolescence remains below national public health targets (≥ 95% for MenACWY and HPV, and ≥ 90% for the dTap-IPV booster by 15 years of age) [2, 5, 6]. Persistently low coverage rates have long-term health consequences, increasing the risk of HPV-related cancers [7] and the long-term sequelae of IMD [8]. Adolescents also play a pivotal epidemiological role: the intensified social interactions characteristic of this life stage elevate the risk of disease carriage and transmission, making this age group central to efforts aimed at disrupting transmission chains and protecting the broader community [8]. Because adolescents comprise approximately 16% and 9% of the global [9] and Italian populations [10], respectively, they represent a critical target group for immunization. Furthermore, adolescence is a unique developmental stage of life marked by a shift in healthcare decision-making dynamics, parental authority gradually gives way to the emerging autonomy of the young individual, creating a complex environment where multiple factors contribute to low vaccination rates [11]. This period is also when individuals begin to develop health-related attitudes and behaviors that tend to persist into adulthood, presenting a crucial opportunity to shape long-term engagement with preventive care [1]. Therefore, understanding vaccination adherence at this stage is essential for designing and implementing tailored interventions. In this context, the primary objective of this study is two fold: to investigate past vaccine uptake during adolescence and to assess the current vaccination willingness among a sample of young adults (university students aged 18–29 years). To evaluate this, we retrospectively analyzed their adolescent vaccination histories alongside their present intentions. A secondary aim is to identify the factors predicting both past uptake and current willingness, with the ultimate goal of informing targeted interventions to improve immunization coverage during adolescence in Italy. Methods Study design, setting and study populations The present study used a cross-sectional design and was conducted over a 4-week period, between March 4 and April 4, 2023, at the “Magna Græcia” University of Catanzaro, in southern Italy. The study population consisted of young adults (university students aged 18–29 years) who were surveyed to retrospectively investigate their immunization history during adolescence, in accordance with the recommendations of the National Immunization Prevention Plan 2023–2025 [2]. To participate in this study, participants were required to fulfill the following inclusion criteria: (i) age between 18 and 29 years old, (ii) current enrollment as an undergraduate “Magna Græcia” university student, and (iii) proficiency in reading and comprehending the Italian language. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for observational studies [12] were followed in reporting of this research. Data collection In accordance with the data collection framework established in a previous study the authors [13], approval was obtained from the university administration, which subsequently provided a sampling frame of eligible students. An institutional email containing a link to an anonymous online questionnaire (Google Forms®) was then sent to all eligible individuals. The survey opened with an explanatory section detailing the study’s primary objectives. Participants were assured of the voluntary and strictly anonymous nature of the research, guaranteeing complete data confidentiality and the right to withdraw at any time without penalty. Furthermore, the introduction explicitly stated that no financial compensation or incentives would be provided, that all data would be used exclusively for research purposes, and that submission of the completed survey served as implied informed consent. To prevent multiple submissions, the survey was configurated to limit to one response per electronic device. Survey design The survey was developed drawing from previous research on the topic [14–18]. A pretest was conducted among a group of 20 eligible students not included in the final sample to evaluate the comprehensibility, clarity, and ease of administration of the questionnaire. Minor refinements to the survey’s layout were made based on the feedback received during this phase. The final questionnaire (Supplementary Material) was divided into four sections and required approximately 10 min to complete. The first section collected the participants’ sociodemographic characteristics, including gender, age, academic major, and parental education level. The second section assessed adherence to adolescent immunization programs, evaluating both mandatory (the dTap-IPV booster) and recommended (HPV and MenACWY) vaccines. This section additionally explored vaccination history concerning meningococcal disease (e.g., childhood uptake of serogroup B meningococcal vaccine [MenB] and MenC) and current willingness to be vaccinated. To mitigate recall bias, students were instructed to consult their official immunization records prior to completing the survey. The third section investigated the underlying beliefs and personal experiences that shape vaccination decision-making. Finally, the fourth section explored the participants’ sources of information regarding vaccines, their satisfaction with these sources, and their perceived need for further information. To ensure conceptual clarity and prevent overlap between online resource categories, distinct definitions and explicit examples were provided within the survey instrument. Specifically, “social media” was contextualized with examples of major networking platforms (e.g., Facebook, Instagram, X/Twitter), while the “Internet” category referred to general web-based searches and websites. Additionally, the “mass media” category was defined using traditional communication channels, including television, newspapers, and radio. This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Calabria Centre Local Human Research (protocol number: 277, approval date: 15 July 2021) under a unified project framework that encompassed the group’s prior research [14]. Under national regulations, the original protocol maintained continuous validity throughout the study period, as the subsequent data collection (conducted from March 4 to April 4, 2023) fell strictly within the approved project scope and involved no substantial protocol amendments requiring renewal. Statistical analyses Statistical analyses were performed using STATA software, version 19.0 [19]. Categorical variables were expressed as frequency and percentages. The Shapiro-Wilk test was used to estimate the skewness of the variables. When normally distributed, continuous variables were summarized using means and standard deviations (SD), whereas, in cases of deviations from normality, medians and interquartile ranges (IQR) were used. Three logistic regression models were built to investigate the relationship between independent variables and the following outcomes of interest: having received the MenACWY vaccine (Model 1), the HPV vaccine (Model 2), and the dTap-IPV booster (Model 3) during adolescence. The following independent variables were included in the models: gender (male = 0; female = 1), age (in years, continuous), having at least one chronic illness (no = 0; yes = 1), parental education level (both holding a high school diploma or lower = 0; one holding a university degree or higher = 1; both holding a university degree or higher = 2), encountering healthcare worker (HCW) who discouraged vaccination (no = 0; yes = 1), and having a general practitioner who held pro-vaccination attitudes (no = 0; yes = 1). The variable having received the MenC or MenB vaccinations during childhood (no = 0; yes = 1) was included in Model 1. The variable having received the dTap-IPV booster during adolescence (no = 0; yes = 1) was included in Models 1 and 2. The variable having received the HPV vaccination during adolescence (no = 0; yes = 1) was included in Models 1 and 3. The variable having received the MenACWY vaccination during adolescence (no = 0; yes = 1) was included in Models 2 and 3. The statistical significance level was set at a p < 0.05. Adjusted odds ratio (OR) and 95% confidence intervals (CIs) were calculated. Results Sociodemographic characteristics Table 1 summarizes the sociodemographic characteristics of the 527 participating undergraduate students. The mean age of the cohort was 23 years (SD = 2.9), and 8.9% reported having at least one chronic medical condition. The majority of the sample (69.1%) was enrolled in medical or life sciences programs, while 23% were majoring in social sciences. Table 1Sociodemographic characteristics of study participants (N = 527)VariablesMean (± SD) n %Age 23 (± 2.9)Gender Male13225.1 Female39574.9Major attended Technology and Engineering427.9 Social sciences12123 Medical or life sciences36469.1Having at least one chronic illness Yes478.9 No48091.1 Table 1Sociodemographic characteristics of study participants (N = 527)VariablesMean (± SD) n %Age 23 (± 2.9)Gender Male13225.1 Female39574.9Major attended Technology and Engineering427.9 Social sciences12123 Medical or life sciences36469.1Having at least one chronic illness Yes478.9 No48091.1 Sociodemographic characteristics of study participants (N = 527) Adherence to vaccinations during adolescence Table 2 details adolescent vaccine adherence, vaccination willingness, and the underlying reasons. Only 29% of the sample received the MenACWY vaccine during adolescence. The leading drivers for MenACWY vaccination included maintaining an up-to-date immunization status (71.2%), preventing meningococcal disease (66.1%) and severe neurological sequelae (43.1%), and complying with recommendations from HCWs (41.2%) or public health authorities (39.2%). Conversely, among those unvaccinated during adolescence, 48.1% expressed no intention to receive the MenACWY vaccine in the future. The predominant reported reasons were the absence of an HCW recommendation (59.4%), being afraid of serious side effects (e.g., allergic reactions, febrile seizures) (20.3%), low perceived susceptibility to infection (18.8%), and skepticism regarding the benefits of recommended vaccines (10.9%). Notably, 60.1% of the sample had received at least one childhood meningococcal vaccine (20.9% MenB, 12.3% MenC, and 26.9% both). Multivariate analysis (Model 1, Table 3) identified childhood vaccination against both MenB and MenC as the strongest predictor of adolescent MenACWY uptake (OR: 3.44; 95% CI: 2.25–5.29). Additionally, receiving the HPV vaccine during adolescence doubled the likelihood of MenACWY vaccination (OR: 2.12; 95% CI: 1.24–3.63). Table 2Adolescent vaccine adherence, vaccination willingness, and their respective underlying reasonsVariables n %Uptake during adolescence (527 respondents) Yes15329 No37471Reasons for adolescent uptake * (153 respondents) Desire to be up to date with all the recommended vaccinations10971.2 Prevention of meningococcal disease10166.1 Prevention of serious neurological sequelae6643.1 Adherence to HCW recommendation6341.2 Adherence to public health authorities’ recommendations6039.2 Concern about getting infected2516.3 Other42.6Vaccine willingness among unvaccinated participants (133 respondents) # Yes (Intend to get vaccinated)6951.9 No (Do not intend to get vaccinated)6448.1Reasons for intending to get vaccinated* (69 respondents) Prevention of meningococcal disease4666.7 Desire to be up to date with all the recommended vaccinations3550.7 Adherence to public health authorities’ recommendations2536.2 Prevention of serious neurological sequelae3421.3 Adherence to HCW recommendation1115.9 Concern about getting infected68.7 Other34.3Reasons for not intending to get vaccinated* (64 respondents) Lack of recommendation by an HCW3859.4 Being afraid of serious adverse reactions (e.g., allergic reaction, febrile convulsions)1320.3 Low perceived susceptibility to infection1218.8 Skepticism regarding the benefits of recommended vaccines710.9 Being afraid of mild side effects (e.g., pain at injection site, headache, fever, fatigue)46.3 Other23.1 Low perceived benefits of vaccination11.6 Human papillomavirus vaccination Uptake during adolescence (527 respondents) Yes36068.3 No16731.7Reasons for adolescent uptake* (360 respondents) Prevention of HPV-related cancer20155.8 Adherence to HCW recommendation19654.4 Prevention of HPV infection17247.8 Adherence to public health authorities’ recommendations16445.6 Concern about getting infected8022.2 Belief that vaccination was mandatory7220 Other20.6Vaccine willingness among unvaccinated participants (167 respondents) Yes (Intend to get vaccinated)11166.5 No (Do not intend to get vaccinated)5633.5Reasons for intending to get vaccinated* (111 respondents) Prevention of HPV infection6558.6 Prevention of HPV-related cancer6054.1 Adherence to public health authorities’ recommendations5650.5 Adherence to HCW recommendation2623.4 Concern about getting infected2421.6 Belief that vaccination is mandatory43.6Reasons for not intending to get vaccinated* (56 respondents) Low perceived susceptibility to infection2544.6 Low perceived benefits of vaccination1425 Structural barriers to access (e.g., long waiting list at vaccination centers)814.3 Being afraid of serious adverse reactions (e.g., allergic reaction, febrile convulsions)610.7 Lack of belief in the efficacy of the HPV vaccination58.9 Lack of recommendation by an HCW35.4 Being afraid of mild side effects (e.g., pain at injection site, headache, fever, fatigue)23.6 Other23.6 Booster against diphtheria, tetanus, pertussis and poliomyelitis Uptake during adolescence (527 respondents) Yes47189.3 No5610.7Reasons for adolescent uptake* (471 respondents) The vaccine is effective at preventing related illnesses36176.7 The vaccination is mandatory17236.5 Adherence to public health authorities’ recommendations15733.3 Adherence to HCW recommendation15031.8 Concern about getting infected418.7 Other61.3Vaccine willingness among unvaccinated participants (56 respondents) Yes (Intend to get vaccinated)3460.7 No (Do not intend to get vaccinated)2239.3Reasons for intending to get vaccinated* (34 respondents) The vaccine is effective at preventing related illnesses2882.4 Adherence to public health authorities’ recommendations1338.2 The vaccination is mandatory617.6 Adherence to HCW recommendation38.9 Concern about getting infected25.9Reasons for not intending to get vaccinated * (22 respondents) Low perceived susceptibility to infection1045.5 Lack of recommendation by an HCW940.9 Being afraid of serious adverse reaction (e.g., allergic reactions, febrile convulsions)313.6 Structural barriers to access (e.g., long waiting list at vaccination centers)29.1 Low perceived benefits of vaccination29.1 Being afraid of mild side effects (e.g., pain at injection site, headache, fever, fatigue)29.1 Other14.6HCW: Healthcare worker; HPV: Human papillomavirus*Multiple answers are allowed#Percentages calculated based on available data Table 2Adolescent vaccine adherence, vaccination willingness, and their respective underlying reasonsVariables n %Uptake during adolescence (527 respondents) Yes15329 No37471Reasons for adolescent uptake * (153 respondents) Desire to be up to date with all the recommended vaccinations10971.2 Prevention of meningococcal disease10166.1 Prevention of serious neurological sequelae6643.1 Adherence to HCW recommendation6341.2 Adherence to public health authorities’ recommendations6039.2 Concern about getting infected2516.3 Other42.6Vaccine willingness among unvaccinated participants (133 respondents) # Yes (Intend to get vaccinated)6951.9 No (Do not intend to get vaccinated)6448.1Reasons for intending to get vaccinated* (69 respondents) Prevention of meningococcal disease4666.7 Desire to be up to date with all the recommended vaccinations3550.7 Adherence to public health authorities’ recommendations2536.2 Prevention of serious neurological sequelae3421.3 Adherence to HCW recommendation1115.9 Concern about getting infected68.7 Other34.3Reasons for not intending to get vaccinated* (64 respondents) Lack of recommendation by an HCW3859.4 Being afraid of serious adverse reactions (e.g., allergic reaction, febrile convulsions)1320.3 Low perceived susceptibility to infection1218.8 Skepticism regarding the benefits of recommended vaccines710.9 Being afraid of mild side effects (e.g., pain at injection site, headache, fever, fatigue)46.3 Other23.1 Low perceived benefits of vaccination11.6 Human papillomavirus vaccination Uptake during adolescence (527 respondents) Yes36068.3 No16731.7Reasons for adolescent uptake* (360 respondents) Prevention of HPV-related cancer20155.8 Adherence to HCW recommendation19654.4 Prevention of HPV infection17247.8 Adherence to public health authorities’ recommendations16445.6 Concern about getting infected8022.2 Belief that vaccination was mandatory7220 Other20.6Vaccine willingness among unvaccinated participants (167 respondents) Yes (Intend to get vaccinated)11166.5 No (Do not intend to get vaccinated)5633.5Reasons for intending to get vaccinated* (111 respondents) Prevention of HPV infection6558.6 Prevention of HPV-related cancer6054.1 Adherence to public health authorities’ recommendations5650.5 Adherence to HCW recommendation2623.4 Concern about getting infected2421.6 Belief that vaccination is mandatory43.6Reasons for not intending to get vaccinated* (56 respondents) Low perceived susceptibility to infection2544.6 Low perceived benefits of vaccination1425 Structural barriers to access (e.g., long waiting list at vaccination centers)814.3 Being afraid of serious adverse reactions (e.g., allergic reaction, febrile convulsions)610.7 Lack of belief in the efficacy of the HPV vaccination58.9 Lack of recommendation by an HCW35.4 Being afraid of mild side effects (e.g., pain at injection site, headache, fever, fatigue)23.6 Other23.6 Booster against diphtheria, tetanus, pertussis and poliomyelitis Uptake during adolescence (527 respondents) Yes47189.3 No5610.7Reasons for adolescent uptake* (471 respondents) The vaccine is effective at preventing related illnesses36176.7 The vaccination is mandatory17236.5 Adherence to public health authorities’ recommendations15733.3 Adherence to HCW recommendation15031.8 Concern about getting infected418.7 Other61.3Vaccine willingness among unvaccinated participants (56 respondents) Yes (Intend to get vaccinated)3460.7 No (Do not intend to get vaccinated)2239.3Reasons for intending to get vaccinated* (34 respondents) The vaccine is effective at preventing related illnesses2882.4 Adherence to public health authorities’ recommendations1338.2 The vaccination is mandatory617.6 Adherence to HCW recommendation38.9 Concern about getting infected25.9Reasons for not intending to get vaccinated * (22 respondents) Low perceived susceptibility to infection1045.5 Lack of recommendation by an HCW940.9 Being afraid of serious adverse reaction (e.g., allergic reactions, febrile convulsions)313.6 Structural barriers to access (e.g., long waiting list at vaccination centers)29.1 Low perceived benefits of vaccination29.1 Being afraid of mild side effects (e.g., pain at injection site, headache, fever, fatigue)29.1 Other14.6HCW: Healthcare worker; HPV: Human papillomavirus*Multiple answers are allowed#Percentages calculated based on available data Adolescent vaccine adherence, vaccination willingness, and their respective underlying reasons HCW: Healthcare worker; HPV: Human papillomavirus *Multiple answers are allowed #Percentages calculated based on available data Table 3Results of the regression models for the potential determinants of having received the MenACWY and HPV vaccination, and the dTap-IPV booster during adolescenceModel 1. Outcome: having received the MenACWY vaccination Log likelihood = -291.85803; Prob > chi2 < 0.0000; Obs = 527 VariablesOR95% CIp-valueChildhood meningococcal vaccination status Having received the MenB or Men C vaccinations or none*1.00 Having received both the MenB and Men C vaccinations3.442.25–5.29< 0.001Having received the HPV vaccination during adolescence No*1.00 Yes2.121.24–3.630.006Having received the dTap-IPV booster No*1.00 Yes1.880.84–4.200.126Gender Male*1.00 Female0.700.42–1.190.188Encountering an HCW who discouraged vaccination No*1.00 Yes0.790.50–1.240.301Age in years, continuous1.040.97–1.130.230Having a general practitioner who held pro-vaccination attitudes No*1.00 Yes1.320.60–2.880.487Having at least one chronic illness No*1.00 Yes0.880.42–1.830.728Parents’ education level Both holding a high school diploma or lower1.00 One parent holding a university degree or higher0.920.54–1.570.757 Both holding a university degree or higher1.010.58–1.780.952Model 2. Outcome: having received the HPV vaccination Log likelihood = -236.09798; Prob > chi2 < 0.0000; Obs = 527 Gender Male*1.00 Female13.758.14–23.53< 0.001Age in years, continuous0.760.70–0.83< 0.001Having received the MenACWY vaccination during adolescence No*1.00 Yes2.321.35–3.970.002Encountering an HCW who discouraged vaccination No*1.00 Yes0.480.29–0.790.004Having received the dTap-IPV booster No*1.00 Yes2.431.21–4.890.013Parents’ education level Both holding a high school diploma or lower1.00 One parent holding a university degree or higher2.141.11–4.120.022 Both holding a university degree or higher0.800.44–1.470.472Having at least one chronic illness No*1.00 Yes0.680.32–1.440.311Having a general practitioner who held pro-vaccination attitudes No*1.00 Yes0.410.16–1.050.064Model 3. Outcome: having received the dTap-IPV booster Log likelihood = -166.50878; Prob > chi2 < 0.0026; Obs = 527 Having received the HPV vaccination during adolescence No*1.00 Yes2.321.18–4.600.015Having received the MenACWY vaccination during adolescence No*1.00 Yes2.321.06–5.120.036Age in years, continuous0.920.83–1.020.108Having at least one chronic illness No*1.00 Yes2.620.75–9.110.130Gender Male*1.00 Female0.830.41–1.720.633Parents’ education level Both holding a high school diploma or lower1.00 One parent holding a university degree or higher0.680.33–1.400.299 Both holding a university degree or higher1.290.54–3.080.566Encountering an HCW who discouraged vaccination No*1.00 Yes0.800.43–1.480.468Having a general practitioner who held pro-vaccination attitudes No*1.00 Yes0.770.25–2.370.64795% CI: 95% Confidence Interval: MenACWY: Serogroup A, C,W and Y meningococcal vaccine; MenB: Serogroup B meningococcal vaccine; MenC: Serogroup C menigococcal vaccine; dTap-IPV Diphtheria, Tetanus, acellular Pertussis and Inactivated Poliovirus Vaccine; HCW: Healthcare Worker; HPV: Human papillomavirus; OR: Odds Ratio*Reference category Table 3Results of the regression models for the potential determinants of having received the MenACWY and HPV vaccination, and the dTap-IPV booster during adolescenceModel 1. Outcome: having received the MenACWY vaccination Log likelihood = -291.85803; Prob > chi2 < 0.0000; Obs = 527 VariablesOR95% CIp-valueChildhood meningococcal vaccination status Having received the MenB or Men C vaccinations or none*1.00 Having received both the MenB and Men C vaccinations3.442.25–5.29< 0.001Having received the HPV vaccination during adolescence No*1.00 Yes2.121.24–3.630.006Having received the dTap-IPV booster No*1.00 Yes1.880.84–4.200.126Gender Male*1.00 Female0.700.42–1.190.188Encountering an HCW who discouraged vaccination No*1.00 Yes0.790.50–1.240.301Age in years, continuous1.040.97–1.130.230Having a general practitioner who held pro-vaccination attitudes No*1.00 Yes1.320.60–2.880.487Having at least one chronic illness No*1.00 Yes0.880.42–1.830.728Parents’ education level Both holding a high school diploma or lower1.00 One parent holding a university degree or higher0.920.54–1.570.757 Both holding a university degree or higher1.010.58–1.780.952Model 2. Outcome: having received the HPV vaccination Log likelihood = -236.09798; Prob > chi2 < 0.0000; Obs = 527 Gender Male*1.00 Female13.758.14–23.53< 0.001Age in years, continuous0.760.70–0.83< 0.001Having received the MenACWY vaccination during adolescence No*1.00 Yes2.321.35–3.970.002Encountering an HCW who discouraged vaccination No*1.00 Yes0.480.29–0.790.004Having received the dTap-IPV booster No*1.00 Yes2.431.21–4.890.013Parents’ education level Both holding a high school diploma or lower1.00 One parent holding a university degree or higher2.141.11–4.120.022 Both holding a university degree or higher0.800.44–1.470.472Having at least one chronic illness No*1.00 Yes0.680.32–1.440.311Having a general practitioner who held pro-vaccination attitudes No*1.00 Yes0.410.16–1.050.064Model 3. Outcome: having received the dTap-IPV booster Log likelihood = -166.50878; Prob > chi2 < 0.0026; Obs = 527 Having received the HPV vaccination during adolescence No*1.00 Yes2.321.18–4.600.015Having received the MenACWY vaccination during adolescence No*1.00 Yes2.321.06–5.120.036Age in years, continuous0.920.83–1.020.108Having at least one chronic illness No*1.00 Yes2.620.75–9.110.130Gender Male*1.00 Female0.830.41–1.720.633Parents’ education level Both holding a high school diploma or lower1.00 One parent holding a university degree or higher0.680.33–1.400.299 Both holding a university degree or higher1.290.54–3.080.566Encountering an HCW who discouraged vaccination No*1.00 Yes0.800.43–1.480.468Having a general practitioner who held pro-vaccination attitudes No*1.00 Yes0.770.25–2.370.64795% CI: 95% Confidence Interval: MenACWY: Serogroup A, C,W and Y meningococcal vaccine; MenB: Serogroup B meningococcal vaccine; MenC: Serogroup C menigococcal vaccine; dTap-IPV Diphtheria, Tetanus, acellular Pertussis and Inactivated Poliovirus Vaccine; HCW: Healthcare Worker; HPV: Human papillomavirus; OR: Odds Ratio*Reference category Results of the regression models for the potential determinants of having received the MenACWY and HPV vaccination, and the dTap-IPV booster during adolescence 95% CI: 95% Confidence Interval: MenACWY: Serogroup A, C,W and Y meningococcal vaccine; MenB: Serogroup B meningococcal vaccine; MenC: Serogroup C menigococcal vaccine; dTap-IPV Diphtheria, Tetanus, acellular Pertussis and Inactivated Poliovirus Vaccine; HCW: Healthcare Worker; HPV: Human papillomavirus; OR: Odds Ratio *Reference category Regarding the HPV vaccine, 68.3% of the students reported receiving it during adolescence. The most frequent reasons for uptake were the prevention of HPV-related cancers (55.8%) and infections (47.8%), followed by HCW recommendations (54.4%) and compliance with public health authorities’ recommendations (45.6%). Conversely, among those who remained unvaccinated during adolescence, 33.7% expressed no intention of receiving the HPV vaccine in the future. The primary barriers to uptake included a low perceived risk of infection (44.6%), skepticism regarding the vaccine’s benefits (25%), limited access to vaccination facilities (e.g., long waiting lists) (14.3%), and being afraid of serious side effects (e.g., allergic reactions, febrile seizures) (10.7%). Multivariate analysis (Model 2, Table 3) indicated that adolescent HPV vaccination was strongly associated with both the MenACWY vaccination (OR: 2.32; 95% CI: 1.35–3.97) and the dTap-IPV booster uptake (OR: 2.43; 95% CI: 1.21–4.89). Furthermore, female sex (OR: 13.75; 95% CI: 8.14–23.53), younger age (OR: 0.76; 95% CI: 0.70–0.83), and having at least one parent with a university degree (OR: 2.14; 95% CI: 1.11–4.12) emerged as positive predictors of HPV vaccination. In contrast, interacting with an HCW who discouraged vaccination (OR: 0.48; 95% CI: 0.29–0.79) was a significant negative predictor. A vast majority of the students (89.4%) reported receiving the dTap-IPV booster during adolescence. For this group, the most frequently cited reasons for vaccination were the vaccine’s effectiveness in preventing related illnesses (76.7%), its mandatory status (36.5%), compliance with public health recommendations (33.3%), and HCW advice (31.8%). Among individuals unvaccinated during adolescence, 39.3% indicated they would not receive the dTap-IPV booster in the future. The leading reasons for this hesitancy were a low perceived risk of infection (45.5%), the absence of an HCW recommendation (40.9%), and being afraid of serious side effects (13.6%). Finally, Model 3 (Table 3) demonstrated that receiving the dTap-IPV booster was positively associated with the uptake of both the HPV (OR: 2.32; 95% CI: 1.18–4.60) and MenACWY (OR: 2.32; 95% CI: 1.06–5.12) vaccines. Beliefs and experiences regarding vaccination decision-making Nearly all participants (98.9%) believed that vaccination decisions should be made independently, free from the influence of family or friends, and 93.9% recognized that an overabundance of conflicting information could negatively impact vaccine uptake. A vast majority of the sample (92%) indicated that their general practitioner held pro-vaccination attitudes. Notably, 31.1% of respondents reported being advised against vaccination by an HCW; the most frequent medical justifications for this were allergies (36%) and the presence of a chronic disease (21.3%). Additionally, 25.1% of the overall sample reported that an HCW had discouraged vaccination based on the belief that potential harms (e.g., safety concerns, side effects, or a lack of long-term data) outweighed the benefits of specific vaccines. Finally, approximately one in ten students (10.8%) reported having friends who held anti-vaccination views. Sources of information on vaccinations HCWs served as the primary source of vaccine information for almost all participants (99.4%). Additional sources included family and friends (91.5%), the Internet (88.8%), traditional mass media (e.g., television, newspapers, radio) (81.6%), and social media platforms (e.g., Facebook, Instagram, Twitter) (80.6%). Satisfaction was highest for information provided by HCWs (94.7%), followed distantly by information from family and friends (39.1%). Nevertheless, nearly half of the respondents (45.7%) expressed a need for further information on the topic. Discussion The findings of the present study highlight a significant gap in adolescent immunization and provide thorough insights into the factors influencing vaccination uptake. Adherence to recommended vaccinations during adolescence is crucial for sustaining childhood protection and preventing specific infectious diseases. Therefore, collecting data and generating evidence on strategies to improve vaccination adherence is pivotal. One of the key findings of the study is the alarmingly low uptake of the MenACWY vaccination (29%) among the enrolled individuals, falling drastically short of the ≥ 95% target set by the Italian Ministry of Health [2]. Because adolescents serve as the primary reservoir of meningococcal carriage [20], achieving high vaccine coverage in this demographic not only confers direct protection but also reduces carriage prevalence in the broader population, thereby fostering community immunity across all age groups [21, 22]. For instance, evidence from the UK MenACWY program demonstrated that achieving 84% coverage in school cohorts aged 14 to 19 years led to substantial reductions in both meningococcal carriage and invasive disease among vaccinated and unvaccinated populations [22]. While existing literature suggests that socioeconomic factors and limited healthcare access often drive coverage disparities [23], this does not fully explain the Italian context, where the National Health Service provides all scheduled mandatory and recommended vaccines (including MenACWY) free of charge. Instead, the relatively low incidence of IMD in Italy [24] may partially explain the poor uptake observed in this study. The perception that this disease is no longer widespread, coupled with a low perceived susceptibility to infection, can significantly depress vaccination rates [25]. Supporting this, our results identified a low perceived risk of infection and fear of severe side effects as the two most prominent barriers to vaccination willingness. Prior research has shown that the decision to vaccinate is often hindered by an “unbalanced risk” scenario, where the perceived risks of adverse vaccine events outweigh the perceived benefits [13, 26, 27], a phenomenon particularly prevalent among young and healthy individuals. Notably, MenACWY vaccination uptake was significantly higher among individuals who were up to date with other recommended vaccines, such as HPV and MenB. This highlights a consistent pattern in immunization - an “all-or-nothing” behavior - where vaccination against one disease serves as a strong predictor of adherence to the broader national immunization schedule. This finding suggests that vaccine uptake is fundamentally a clustered behavior. Similarly, overall HPV vaccination uptake remained suboptimal (68.3%), falling well short of both the national target of ≥ 95% [2] and the World Health Organization’s global goal of ≥ 90% for the elimination of cervical cancer [28]. The higher uptake of the HPV vaccine compared to the MenACWY vaccine can likely be attributed to the numerous local, regional, and national awareness campaigns promoted over the years [29–32]. Furthermore, beyond preventing HPV infection, the vaccine plays a critical role in preventing cervical and other HPV-associated malignancies, which was the primary motivator for uptake reported in our sample. The finding that female sex was a positive predictor of HPV vaccination likely stems from early public health initiatives that exclusively targeted adolescent females. Consequently, many parents and healthcare providers historically framed HPV as a “female issue,” often overlooking its causal role in anal, penile, and oropharyngeal cancers in males. Although HPV has progressively been recognized as a comprehensive public health priority - resulting in gender-neutral vaccine recommendations for all adolescents [33, 34] - disparities persist. Therefore, public health authorities must focus on maximizing adherence by emphasizing that vaccination is the most effective and economical strategy for reducing HPV-related morbidity and mortality across all sexes. Uptake of the dTap-IPV booster fell marginally short of the Italian Ministry of Health’s ≥ 90% target (89.4%). However, this high coverage was anticipated; unlike the other vaccines assessed, the dTap-IPV booster is legally mandated, a status that emerged as the second most frequent motivator for uptake. As established in the literature, mandatory policies remain a highly effective tool for maximizing vaccination coverage [35]. Consistent with prior research [13, 26, 27, 36], HCW recommendations also proved to be a critical driver of vaccine acceptance, with adherence to HCW advice frequently cited as a primary reason for receiving the booster. Conversely, the absence of such recommendations highlights that substantial missed vaccination opportunities stem from provider- and practice-level barriers [37]. To minimize these missed opportunities, medical organizations recommend supporting HCWs with evidence-based interventions, such as electronic medical record prompts, standing orders, and reminder/recall systems, to ensure every clinical encounter facilitates immunization access [38, 39]. Despite the critical role of providers, a concerning pattern emerged regarding the quality of HCW guidance. Among participants who were explicitly discouraged from vaccinating by an HCW, the justifications provided were frequently a history of allergies or a chronic illness. Far from being true contraindications, these medical conditions typically necessitate prioritization for vaccination due to the patients’ elevated risk of severe infectious complications [40, 41]. This unwarranted vaccine deferral likely reflects a broader tendency among some HCWs to overestimate perceived risks relative to documented clinical benefits [42]. Cumulative evidence indicates that provider misconceptions regarding vaccine safety significantly undermine the proactive promotion of immunization, whereas robust clinical knowledge and positive attitudes are the strongest predictors of a provider recommending a vaccine [43–45]. Because the vast majority of students in the sample identified HCWs as their primary source of vaccine information, strengthening provider competency in vaccine counseling is not merely a training objective, but a vital public health imperative. Individual determinants of vaccine hesitancy, such as a lack of trust in vaccine safety and a low perceived risk of infection, were frequently cited reasons for a lack of willingness to get vaccinated. A growing body of evidence has shown that personal perceptions, attitudes, and demographic characteristics lead adolescents to delay or refuse vaccination, even when free services are available [1]. It also should be noted that the development of autonomy in healthcare decision-making during adolescence is a critical determinant of lifelong health-seeking behaviors [46]. Research suggests that when health literacy regarding specific immunizations, such as the HPV or meningococcal vaccines, is prioritized, adolescents can transition from passive recipients to active health advocates within their social networks [47, 48]. The practical impact of this transition is amplified by integrating digital literacy tools and peer-led frameworks, which align health interventions with the daily digital reality of modern youth [49]. Consequently, effective immunization strategies must adopt a dual-targeted approach that engages both adolescents and their parents/guardians. Addressing these two primary decision-makers simultaneously creates a synergy that moves beyond standard clinical outreach. This developmental shift can be supported by shared decision-making tools, such as joint educational apps or guided scripts, that harmonize the adolescent’s drive for independence with the parent’s protective instincts [50, 51]. At a systemic level, this framework could be operationalized through “low-friction” policies, such as school-based clinics that resolve logistical barriers for parents, combined with “pain-free” clinical protocols to mitigate adolescent procedural anxiety [52, 53]. By bridging these psychological, social, and structural domains, healthcare systems can effectively nurture lifelong health-seeking behaviors and improve population-level immunization outcomes. Finally, adherence to public health authorities’ recommendations emerged as a reason for having received the dTap-IPV booster. This underscores the need for national and local public health authorities to enhance their policymaking through culturally sensitive evidence-based interventions. In this context, public health campaigns should shift the narrative to emphasize that vaccination is not merely a personal choice, but a matter of social responsibility, positioning immunization as a civic duty that serves the best interests of the broader community. Limitations This study has several methodological limitations that should be considered when interpreting the findings. First, the cross-sectional design precludes causal inferences regarding the observed associations. Nevertheless, this approach provides valuable baseline data on adolescent MenACWY and HPV vaccine uptake, generating hypotheses for future research and informing the development of targeted public health interventions. Second, self-reported vaccination histories are inherently subject to recall bias, particularly for vaccines administered several years prior. To mitigate this, participants were explicitly instructed to consult their official immunization records before completing the questionnaire. Third, the survey did not explicitly verify whether participants resided in Italy during their adolescence, raising the possibility of differential exposure to the national immunization schedule. However, institutional registry data from the study period confirm that students who obtained their secondary school diplomas abroad account for only 1.2% to 1.6% of the population at the “Magna Græcia” University of Catanzaro [54]. Using secondary education as a proxy for adolescent residency, over 98% of the sample likely spent their formative years within the Italian healthcare system. Thus, the potential confounding effect of foreign-raised participants on the observed coverage rates is negligible. Finally, the sample consisted predominantly of students enrolled in medical or life science programs, potentially introducing selection bias. While this distribution closely mirrors the baseline demographics of the institution - where these programs account for approximately 70% of total enrollment - it has distinct implications for the generalizability of the findings. However, the impact on historical adolescent vaccination rates is likely minimal, as those vaccinations occurred prior to university enrollment, whereas the high concentration of health-oriented students may lead to an overestimation of current and future vaccination willingness. Students in these disciplines typically possess higher baseline health literacy and a stronger engagement with preventive medicine, which may skew attitudinal data toward greater vaccine intention compared to the broader young adult population. Conclusions This study highlights significant shortfalls in the adolescent uptake of recommended MenACWY and HPV vaccines in Italy. Conversely, high adherence to the mandatory dTap-IPV booster underscores the efficacy of mandates, while the strong correlation in individual uptake across different vaccines indicates a “clustered behavior” toward immunization. Although HCWs are the primary drivers of vaccine acceptance, missed clinical opportunities and unwarranted vaccine deferrals constitute major systemic barriers. Furthermore, an “unbalanced risk” perception - driven by a low perceived susceptibility to disease and exaggerated fears of side effects - heavily limits voluntary uptake. To improve coverage and nurture lifelong health-seeking behaviors, interventions must strengthen HCW counseling competencies and utilize “low-friction” delivery models, such as school-based clinics. Ultimately, public health strategies must adopt a dual-targeted approach that engages both adolescents and parents, reframing vaccination from an individual medical choice to a vital social responsibility. Supplementary Information Supplementary Material 1. Supplementary Material 1.